Dr. Bronner’s Donates $1 Mil to Legalize Medical Psilocybin in Oregon

Dr. Bronner's Soaps is on a mission to overturn psychedelic prohibition—starting with Oregon

Shelby Hartman // April 28, 2020

DoubleBlind is devoted to fair, rigorous reporting by leading experts and journalists in the field of psychedelics. Read more about our editorial process and fact-checking here. Editorially reviewed by Madison Margolin.

On Monday, April 27, David Bronner, CEO of Dr. Bronner’s Magic Soaps, announced that his company is donating one million dollars to the campaign to legalize medical psilocybin in Oregon this year. This follows a $150,000 donation that Dr. Bronner’s made to the initiative last September.

Initiative Petition 34 currently has 130,691 of the 145,000 signatures needed to get on the ballot in November. If it passes, psilocybin, the psychoactive component in psychedelic mushrooms, will be legal for all adults in the state in a therapeutic setting, as long as it’s deemed safe for the person.

There are currently initiatives taking shape around the country to overturn the prohibition of entheogenic plants and fungi. Last May, Denver became the first county in the country to decriminalize psilocybin. Less than a month later, Oakland’s city council passed a resolution blocking funds from being used to prosecute people for the possession of naturally-occurring psychedelics. The campaign behind the resolution, Decriminalize Nature, now has initiatives taking shape in more than 100 cities and counties across the U.S., and in Canada.

DoubleBlind presents: How to grow mushrooms online course. Let's Shroom!

Initiative Petition 34, or IP34, is fundamentally different from those decriminalization efforts, however. It includes a state-legal infrastructure for the manufacturing of psilocybin. It also includes licensed settings where psilocybin would be administered by trained facilitators, informed by research that’s been conducted at institutions such as Johns Hopkins and New York University. The state-legal psilocybin sessions, like the clinical trials at these universities, would include preparation, the session itself, and what’s called psychedelic integration, where a trained therapist helps the participant process their psychedelic experience after it’s over.

There’s been some controversy in the psychedelic community about whether IP34 is the best model for overturning prohibition. As DoubleBlind reported in 2019, some groups feel strongly that decriminalization—so people can simply, no longer, be criminalized for possessing drugs—should be the priority over medicalization. Others feel that psilocybin—or any drug, for that matter—should not be legalized by states, but by the federal government, once it’s made it through the entire FDA-approval process. (Psilocybin is currently in the last phase of studies for treatment-resistant depression through the FDA.)

In a press release put out by Bronner in 2019, he recognized these divisions within the psychedelic field, writing: “I want to acknowledge the concern from various quarters in the research community invested in the FDA approval process—that Oregon’s ballot measure goes too far too fast, and threatens to create a cultural and regulatory backlash against all the progress they are making, much like occurred in the 60’s.” He said, however, that “the state ballot measure process is the only political mechanism that exists for providing this kind of broad responsible adult access.” Much like cannabis, Bronner hopes IP34 will push federal regulators to respect the autonomy of states.

Of course, we’ll only get to see how the feds respond if the initiative actually passes. It appears at this point that there’s a good chance it will. A poll conducted by the campaign in February of last year found 47 percent of Oregonians were in favor (“yes” or “leaning yes”), 46 percent were opposed (“no” or “leaning no”) and 7 percent were undecided about the initiative.

Shelby Hartman is DoubleBlind’s Editor-in-Chief.

We have a small favor to ask. In 2020, more than five million readers like you visited DoubleBlind’s website. Many of them are suffering and simply seeking trusted information on how to use psychedelics to heal.

We started DoubleBlind two years ago at a time when even the largest magazines and media companies were cutting staff and going out of business. Friends and family said we were crazy. But we did it anyway, because we believe in it—deeply. We believe in the value of good journalism. And we believe in the extraordinary potential of psychedelics to reduce suffering. At the time we made a commitment: we will never have a paywall, we will never rely on advertisers we don’t believe in to fund our reporting, and we will always be accessible via email and social media to support people for free on their journeys with plant medicines.

To help us do this, if you feel called and can afford it, we ask you to consider making a monthly donation to DoubleBlind, starting at $1. In exchange, you’ll be invited to a monthly Zoom call with DoubleBlind’s co-founders, Shelby Hartman and Madison Margolin, where they’ll answer any questions you have about the psychedelic movement or your own journey with psychedelics. These Zoom calls also include special guests, some of the people who we love and respect most in the psychedelic space. Together, we brainstorm, collaborate, dialogue, and, simply, commune. Either way, please know that we value you as a member of our community. Make a gift now from as little as $1. Thank you.

Donate now
Shelby Hartman is Co-Founder and Editor-in-Chief of DoubleBlind. Her work has appeared in VICE, Quartz, the Huffington Post, and Rolling Stone, among others. Shelby worked in broadcast news production for CBS News covering presidential elections, protests, natural disasters, and other breaking news. Spurred by a passion for print and investigative reporting, she transitioned to magazine writing, working as an editor at Pasadena Magazine and receiving her Master’s Degree in long-form journalism from Columbia University in 2015. Since then, Shelby has worked as a columnist at LA Weekly and an editor at Herb, the largest cannabis media company, with extensive features on post-traumatic stress disorder in the veteran community, the cannabis industry, the psychedelic research boom, and the popularization of ayahuasca. You can follow her on Twitter, Instagram and LinkedIn



You Can Now Get Ketamine in the Mail for Your Depression

Take home ketamine and online therapy are helping people cope with the COVID-19 crisis.

Why Kava is a Beautiful, Legal Way to Treat Anxiety, Build Community, and Create Ritual

Kava is known for its mellow, relaxing effect. Now DoubleBlind has partnered with Potent Kava so you can try it at home.

Thanks to COVID-19, Magic Mushrooms Will Remain Illegal in California—For Now

Social distancing measures have halted Decriminalize California’s attempts to reform the state’s psilocybin laws.